GlassScriptPhysician profile
Jill Gore
NPI 1093741332
$3,029.80
in general payments reported to CMS, 2019-2025
22 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.53 · 2022: $183 · 2023: $621 · 2024: $1,000 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,747.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $352.33 | 2023-2025 | Otezla, Krystexxa |
| Abbott Laboratories | $272.65 | 2024-2025 | Freestyle Libre 3 |
| Globus Medical, INC. | $173.83 | 2025 | Senza |
| Medtronic, INC. | $152.02 | 2023 | Interstim |
| Inspire Medical Systems, INC. | $149.92 | 2024 | Inspire |
| Pfizer INC. | $147.83 | 2024-2025 | |
| Kerecis Limited | $145.71 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Teva Pharmaceuticals USA, INC. | $140.00 | 2024 | Austedo Xr |
| Mirum Pharmaceuticals, INC. | $134.66 | 2025 | Livmarli |
| Insightec,INC | $133.27 | 2024 | Exablate |
| Inari Medical, INC. | $132.26 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Phathom Pharmaceuticals, INC. | $121.77 | 2024 | Voquezna |
| Genzyme Corporation | $121.36 | 2025 | |
| Gilead Sciences, INC. | $118.33 | 2024 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $117.05 | 2023-2025 | Fasenra, Airsupra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $103.69 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $99.54 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $99.53 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.77 | 2023 | |
| Novo Nordisk INC | $83.03 | 2022 | |
| Phadia US INC. | $81.55 | 2025 | Immunocap |
| Janssen Pharmaceuticals, INC | $57.70 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Gore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.